Panbela Therapeutics (PBLA) Competitors $0.16 0.00 (0.00%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. RDHL, CNSP, ARAV, LIPO, QLGN, SPRC, PRFX, ELAB, ENVB, and PCSAShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Redhill Biopharma (RDHL), CNS Pharmaceuticals (CNSP), Aravive (ARAV), Lipella Pharmaceuticals (LIPO), Qualigen Therapeutics (QLGN), SciSparc (SPRC), PainReform (PRFX), PMGC (ELAB), Enveric Biosciences (ENVB), and Heatwurx (PCSA). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors Redhill Biopharma CNS Pharmaceuticals Aravive Lipella Pharmaceuticals Qualigen Therapeutics SciSparc PainReform PMGC Enveric Biosciences Heatwurx Redhill Biopharma (NASDAQ:RDHL) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends. Which has preferable earnings and valuation, RDHL or PBLA? Redhill Biopharma has higher revenue and earnings than Panbela Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$8.04M0.37-$8.27MN/AN/APanbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Is RDHL or PBLA more profitable? Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A Panbela Therapeutics N/A N/A -302.61% Do institutionals & insiders have more ownership in RDHL or PBLA? 7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, RDHL or PBLA? Redhill Biopharma has a beta of 4.18, suggesting that its stock price is 318% more volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Does the media refer more to RDHL or PBLA? In the previous week, Redhill Biopharma had 4 more articles in the media than Panbela Therapeutics. MarketBeat recorded 4 mentions for Redhill Biopharma and 0 mentions for Panbela Therapeutics. Redhill Biopharma's average media sentiment score of 0.25 beat Panbela Therapeutics' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Overall Sentiment Redhill Biopharma Neutral Panbela Therapeutics Neutral SummaryRedhill Biopharma beats Panbela Therapeutics on 8 of the 8 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$767K$833.52M$5.81B$9.76BDividend YieldN/A4.84%4.39%4.06%P/E Ratio0.001.1831.3626.05Price / SalesN/A152.90387.8788.42Price / CashN/A19.5638.0259.36Price / Book-0.016.649.536.60Net Income-$25.26M-$4.94M$3.26B$265.65M7 Day PerformanceN/A1.85%2.14%2.00%1 Month PerformanceN/A3.06%3.22%0.46%1 Year Performance-54.23%12.25%30.18%18.88% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics0.3224 of 5 stars$0.16flatN/A-54.2%$767KN/A0.006RDHLRedhill BiopharmaN/A$1.33+4.7%N/A-85.5%$3.06M$8.04M0.00210Positive NewsCNSPCNS Pharmaceuticals1.6023 of 5 stars$6.57-0.9%$300.00+4,466.2%-94.5%$2.96MN/A0.005News CoveragePositive NewsAnalyst UpgradeShort Interest ↑ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeLIPOLipella PharmaceuticalsN/A$0.64+5.9%N/A-85.8%$2.84M$536.36K-0.164QLGNQualigen TherapeuticsN/A$1.68-2.9%N/A-81.6%$2.76M$4.98M0.0050Positive NewsSPRCSciSparcN/A$5.14-3.7%N/A-39.9%$2.72M$1.31M0.004Positive NewsPRFXPainReform1.2964 of 5 stars$1.35-1.9%N/A+58.2%$2.72MN/A-0.014Positive NewsELABPMGC0.8769 of 5 stars$1.93flatN/A-99.4%$2.66M$1.71M0.0018News CoveragePositive NewsGap DownENVBEnveric Biosciences1.603 of 5 stars$1.07-1.8%$10.00+834.6%-84.8%$2.64MN/A-0.0320PCSAHeatwurx2.5224 of 5 stars$0.22-1.0%$2.00+806.2%-85.0%$2.62MN/A-0.1020 Related Companies and Tools Related Companies Redhill Biopharma Competitors CNS Pharmaceuticals Competitors Aravive Competitors Lipella Pharmaceuticals Competitors Qualigen Therapeutics Competitors SciSparc Competitors PainReform Competitors PMGC Competitors Enveric Biosciences Competitors Heatwurx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access